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This invention includes a ?uorophore-tagged antimalarial 
represented by the following structural formula (1) or a salt 
thereof. This invention relates to the synthesis of ?uorophore 
tagged antimalarials and describes the synthesis of a ?uoro 
phore-tagged antimalarial. These ?uorophore-tagged antima 
larials can be used to image live cells to determine the location 
of the antimalarial in the cell; identify drug resistance and 
groWth related pathways in Plasmodium isolates; identify 
neW drug targets and chemo-sensitiZers to reverse drug resis 
tance. 
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SYNTHESIS AND USE OF 
FLUOROPHORE-TAGGED ANTIMALARIALS 
RELATED APPLICATION 
[0001] This application claims the bene?t of US. Provi 
sional Application No. 61/221,304, ?led on Jun. 29, 2009. 
The entire teachings of the above application are incorporated 
herein by reference. 
BACKGROUND OF THE INVENTION 
[0002] Malaria is a vector-borne infectious disease caused 
by protoZoan parasites and is Widespread in tropical and 
subtropical regions, including parts of the Americas, Asia and 
Africa. Of the ?ve Plasmodium parasite species that can 
infect humans (P falciparum, P vivax, P ovale, P malariae 
and R knowlesi), the most serious forms of the disease are 
caused by R falciparum and R vivax. Of the approximately 
515 million people infected yearly, betWeen one and three 
million people, the majority of Whom are young children in 
Sub-Saharan Africa, die from the disease. 
[0003] Before the emergence of drug-resistant Plasmodium 
strains in the 1960s, chloroquine (CQ) Was a life-saving tool 
in the control of malaria (Greenwood B M, et al., Malaria. 
Lancet. 2005 Apr. 23-29; 365(9469):l487-98; Lalloo D G, et 
al., Lancet Infect Dis. 2006; 6(l2):780-93). Today, only arte 
misinin-based drug combinations can effectively combat all 
parasitic forms of the disease (White, N. J. Malar J, 2008, 7 
Suppl 1, S8). The biomolecular mechanisms of drug-resis 
tance betWeen differing strains of Plasmodium parasites and 
differing types of antimalarial agents are still poorly under 
stood (White, N. J. Drug Resist Updal, 1998, 1, 3-9; Bloland 
P. B., et al., Bull WorldHealZh Organ, 2000, 78, 1378-1388). 
[0004] The current armament of approved anti-malarial 
drugs is limited to only a feW targets Within the human malaria 
parasite. GroWing Widespread resistance to current drugs is 
prompting the development of neW antimalarial agents that 
have neW biological targets. While identi?cation of neW drug 
targets could facilitate the development of effective antima 
larials, neW targets can be dif?cult to identify. Determination 
of cellular accumulation of the antimalarials such as chloro 
quine could help understanding drug action and may lead to 
identi?cation of neW targets. Furthermore, a means to rapidly 
identify drug resistance in the ?eld could lead to quicker 
diagnosis and the administration of appropriate chemo 
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therapy. Therefore, a need exists to develop methods to exam 
ine the interaction of antimalarials Within the Plasmodium 
parasite in order to elucidate neW pathWays that can be 
exploited for the successful treatment of malaria. 
SUMMARY OF THE INVENTION 
[0005] This invention relates to the synthesis of ?uoro 
phore-tagged antimalarials and describes reagents, condi 
tions, methods, routes, and strategies to make ?uorescent 
tagged antimalarials. A ?uorescent-tagged antimalarial has 
been synthesiZed and used to image the accumulation of the 
antimalarial Within a live cell. Fluorophore-tagged antima 
larials can be used to image live cells to locate the antimalarial 
Within or on the cell, screen for drug resistance and identify 
groWth-related pathWays in Plasmodium isolates, and iden 
tify neW drug combinations and neW drug targets. The inven 
tion has many advantages: the ?uorescent tag is not radioac 
tive, the tag is small, and non-toxic, and therefore should not 
interfere With cellular processes. 
[0006] One embodiment of the invention is a compound for 
use in malarial research comprising a coumarin-tagged anti 
malarial, Wherein the coumarin is optionally substituted and 
is connected to the antimalarial through a linker. 
[0007] Another embodiment of the invention is a com 
pound comprising a coumarin-tagged antimalarial compris 
ing coumarin connected to the antimalarial through a linker, 
Wherein the coumarin and linker are represented by the fol 
loWing structural formula: 
or salts thereof. 
[0008] Another embodiment of the invention is a com 
pound represented by the folloWing structural formula: 
or a salt thereof. 
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[0009] Another embodiment of the invention is a com 
pound represented by the following structural formula: 
or a salt thereof. 
[0010] Another embodiment of the invention is a com 
pound represented by the following structural formula: 
Cl N 
or a salt thereof. 
[0011] Another embodiment of the invention is a com 
pound represented by the following structural formula: 
Cl N I \ 
/ 
J 
or a salt thereof. 
[0012] Another embodiment of the invention is a method 
for the identi?cation of a target in a cell, comprising the steps 
of exposing the cell to a ?uorophore-tagged antimalarial 
described herein, allowing the ?uorophore-tagged antima 
larial to bind to its target; capturing the ?uorophore-tagged 
antimalarial bound to the target on an immobiliZed a?inity 
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ligand speci?c for the ?uorophore tag; and identifying the 
target bound to the ?uorophore-tagged antimalarial. 
[0013] Another embodiment of the invention is a method 
for identi?cation of a target in a cell, comprising the steps of 
exposing the cell to the ?uorophore-tagged antimalarial of the 
following structural formula: 
US 2012/0100555 A1 
or a salt thereof; allowing the ?uorophore-tagged antimalarial 
to bind to its target, capturing the ?uorophore-tagged antima 
larial bound to the target on an immobilized a?inity ligand 
speci?c for the ?uorophore tag; and identifying the target 
bound to the ?uorophore-tagged antimalarial. 
[0014] Another embodiment of the invention is a method 
for determining the location of a ?uorophore-tagged antima 
larial Within or on a cell comprising the steps of: exposing the 
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cell to a ?uorophore-tagged antimalarial described herein; 
and assaying the cell to determine the location of the ?uoro 
phore-tagged antimalarial Within or on the cell. 
[0015] Another embodiment of the invention is a method 
for determining the location of a ?uorophore-tagged antima 
larial Within or on a cell comprising the steps of: exposing the 
cell to the ?uorophore-tagged antimalarial of the folloWing 
structural formula: 
or a salt thereof; and assaying the cell to determine the loca 
tion of the ?uorophore-tagged antimalarial Within or on the 
cell. 
[0016] One more embodiment of the invention includes a 
method of preparing a ?uorophore-tagged antimalarial rep 
resented by the folloWing structural formula: 
US 2012/0100555 A1 
or a salt thereof; said method comprising the step of reacting 
a compound represented by the following structural formula: 
or a salt thereof, With an antimalarial represented by the 
folloWing structural formula: 
/ 
Cl N 
or a salt thereof, thereby forming the ?uorophore-tagged anti 
malarial. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0017] FIG. 1 is a graph shoWing the concentration-depen 
dent accumulation of coumarin-labeled chloroquine (CM 
CQ) in different cellular compartments in parasite cells. 
[0018] FIG. 2 is a graph shoWing the IC5O for commercial 
chloroquine (CQ), coumarin (CM) and coumarin-labeled 
chloroquine (CM-CQ). ParasitiZed cultures Were incubated 
for 48 hours With various concentrations of the test com 
pounds and, thereafter, parasitemia Was determined using 
Hoechst staining and ?oW cytometric analyses. 
[0019] FIG. 3 is a graph shoWing the dose-dependent study 
of chloroquine’s effect on JC-l loss (black line) and 
CaspaTag staining (grey line). ParasitiZed cultures Were incu 
bated for 8 hours With different concentrations of chloro 
quine. (n:2) 
[0020] FIG. 4 is a synthetic scheme for CM-CQ (Com 
pound 2). 
[0021] FIG. 5 is a synthetic scheme for Compound 8. 
[0022] FIG. 6 is a synthetic scheme for Compound 13. 
[0023] FIG. 7 is a synthetic scheme for Compound 16. 
[0024] FIG. 8 is a graph shoWing the effects of chemo 
sensitiZers on coumarin-conjugated chloroquine (CM-CQ) 
accumulation in Plasmodium falciparum parasites. Data 
Were obtained by ?oW cytometry. 
[0025] FIG. 9 is a graph shoWing the effects of chemo 
sensitiZers on coumarin-conjugated chloroquine (CM-CQ) 
accumulation in Plasmodiumfalciparum parasites, obtained 
by spectro?uorometer plate readings. 
DETAILED DESCRIPTION OF THE INVENTION 
[0026] Malaria is an infection of red blood cells With the 
single-celled parasite Plasmodium. Malaria parasites are 
transmitted by female Anopheles mosquitoes. The parasites 
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multiply Within red blood cells, causing symptoms that 
include symptoms of anemia (light headedness, shortness of 
breath, tachycardia), as Well as other general symptoms such 
as an enlarged spleen, fatigue, fever, chills, nausea, ?u-like 
illness, and in severe cases, coma and death. 
[0027] The life cycle of malaria parasites in the human 
body starts When a mosquito infects a person by taking a 
blood meal. Next, sporoZoites enter the bloodstream, and 
migrate to the liver. They infect liver cells (hepatocytes), 
Where they multiply into meroZoites, rupture the liver cells, 
and escape back into the bloodstream. Then, the meroZoites 
infect red blood cells, Where they develop into ring forms, 
then trophoZoites (a feeding stage), then schiZonts (a repro 
duction stage), then back into meroZoites. Sexual called 
gametocytes are also produced, Which, if taken up by a mos 
quito, Will infect the insect and continue the life cycle. 
[0028] One embodiment of the invention is a ?uorophore 
tagged antimalarial. A “?uorophore-tagged antimalarial” is a 
compound that includes both a ?uorophore and an antima 
larial moiety. Use of ?uorophore-tagged antimalarials are 
anticipated to not only elucidate promising targets for thera 
peutic drugs, but also enable a greater understanding of the 
physiological role of groWth-related pathWays in unicellular 
organisms. In particular, malaria research includes cellular 
localiZation studies of antimalarials, and elucidation of drug 
targets and groWth-related pathWays. Fluorophore-tagged 
antimalarials can also be used to understand mechanisms of 
drug resistance in Plasmodium species. In particular, the 
localiZation of the labeled drug may be predicted to be dif 
ferent betWeen sensitive and resistant strains. By extension, 
this difference in ?uorescence betWeen sensitive (high ?uo 
rescence) and resistant (loW ?uorescence) strains alloWs the 
use of the labeled drug to identify other drugs that reverses 
resistance by screening for such drugs, termed chemoreversal 
agents or chemosensitiZers, in the presence of the ?uorescent 
tagged antimalarial, that result in high ?uorescence in resis 
tant parasites. 
[0029] As used herein, “?uorophore” is a component of a 
molecule Which causes a molecule to be ?uorescent. It is a 
functional group in a molecule Which Will absorb energy of a 
speci?c Wavelength and re-emit energy at a different (but 
equally speci?c) Wavelength. The amount and Wavelength of 
the emitted energy depend on both the ?uorophore and the 
chemical environment of the ?uorophore. A ?uorophore can 
be selected because it can be used during the 48 hours eryth 
rocytic cycle, is photostable, can be continuously imaged in 
live cells, and has high fatigue strength. High fatigue strength 
refers to the longevity of ?uorescence over long time periods 
(>48 hours) and non-destruction of ?uorophore unit either 
biologically or photochemically). 
[0030] Certain ?uorophore tags, such as coumarin, are bio 
logically inert and therefore non-toxic to malaria parasites. 
Thus, cellular responses to the ?uorophore-tagged antima 
larial should be attributable to the antimalarial component. 
[0031] In a speci?c embodiment, the ?uorophore is cou 
marin. Coumarin is represented by the folloWing structural 
formula: 
US 2012/0100555 A1 
[0032] Derivatives of coumarin are contemplated. For 
example, any substitutable hydrogen on a ring carbon atom 
may be substituted by halo, OH, N02, CN, COOH, COO(Cl - 
C6alkyl), amino, (Cl-C6)alkyl, (Cl-C6)alkoxy, (Cl-C6)alky 
lamino, or di(Cl-C6)alkylamino, Wherein the (Cl-C6)alkyl 
and (Cl-C6)alkoxy in any of the preceeding groups may be 
optionally substituted With halogen, (Cl-C6)alkoxy, OH, 
N02, COOH, COO(Cl -C6alkyl), or CN. In a speci?c embodi 
ment, coumarin is substituted With dimethylamino. 
[0033] In another embodiment, the substituent can be used 
to form the linker and thus be modi?ed to connect the ?uo 
rophore such as coumarin to the antimalarial during the syn 
thesis of the ?uorophore-tagged antimalarial. For example, 
the substituents that can be modi?ed during the synthesis to 
form the linker include a carboxylic acid (eg ‘COOH, 
iCHzCOOH, i(CH2)2COOH, i(CH2)3COOH, i(CH2) 
4COOH, etc., Wherein any of the substitutable hydrogen on a 
carbon atom may be substituted as above) or an ester. In one 
embodiment, the ?uorophore is coumarin substituted With 
dimethylamino and iCHzCOOH. 
[0034] In one embodiment of the invention, the coumarin 
derivative to be incorporated into the ?uorophore-tagged 
antimalarial is 7-dimethylaminocoumarin-4-acetic acid, 
Which is represented by the folloWing structural formula: 
or a salt thereof. 
7-dimethylaminocoumarin-4-acetic acid is knoWn in the art. 
See Goddard J. P. and J. L. Reymond, Trends. Biotechnol. 
2004, 22, 363; Lim N. C. and C. Bruckner, Chem. Commun. 
2004, 1094; Trenor S. R. et al., Chem. Rev. 2004, 104, 3059; 
Lim N. C. et al., Inorg. Chem. 2005, 44, 2018; Gonsalves, M. 
S. T. Chem. Rev. 2009, 109, 190. 
7-dimethylaminocoumarin-4-acetic acid has many suitable 
properties including: 
[0035] photophysical activity (JarZeba, W. G. C. et al., J. 
Phys. Chem. 1998, 92, 7039); 
[0036] non-cytotoxicity (Alexander M. D., et al., Chem 
biochem. 2006, 7, 409); 
[0037] small-size (Fritz M. G., D. Seebach, Helv. Chim. 
Acta 1998, 81, 2414); and 
[0038] Water solubility (Souto A. A., et al., Angew. 
Chem. Int. Ed. Engl. 1995, 34, 2710). 
[0039] Fluorophores other than coumarin can be used in 
this invention. Examples of ?uorophores that can be incorpo 
rated in a ?uorophore-tagged antimalarial include: 
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\ 
Rhodamine 
O O 
Hydroxy Protected Fluorescein 
OEt 
/ 
o OEt 
Naphthopyran 
F F 
Diarylethenes 
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-continued 
No2 
S piropyrans 
Spirobenzopyrans 
O 
\ \ 
O O 
/ 
BODIPY-FI 
The ?uorophores above can be modi?ed to facilitate coupling 
of the ?uorophore to the linker and/ or the antimalarial. 
[0040] A ?uorophore-tagged antimalarial including cou 
marin as the ?uorophore is referred to as a “coumarin-tagged 
antimalarial.” One embodiment of the invention is a com 
pound comprising a coumarin-tagged antimalarial, Wherein 
the coumarin is optionally substituted, as described above, 
and is connected to the antimalarial through a linker. 
[0041] In the ?uorophore-tagged antimalarial, the ?uoro 
phore is attached to the antimalarial (as described beloW) 
through a linker to form the ?uorophore-tagged antimalarial. 
[0042] The linker is a covalent bond, or an alkylene group, 
i.e., i(CH2)xi Where x is a positive integer (for example, 
from 1 to about 18, more speci?cally between 1 and about 10, 
or more speci?cally betWeen 2 and 8, or more speci?cally 
betWeen 4 and 8.) Any substitutable hydrogen on a carbon 
atom in the linker may be substituted by halo, OH, NO2, CN, 
COOH, COO(Cl-C6alkyl), amino, (Cl-C6)alkyl, (Cl-C6) 
alkoxy, (Cl-C6)alkylamino, or di(Cl-C6)alkylamino, 
Wherein the (Cl-C6)alkyl and (Cl-C6)alkoxy in any of the 
preceeding groups may be optionally substituted With halo 
gen, (Cl-C6)alkoxy, COOH, COO(Cl-C6alkyl), OH, NO2 or 
CN. In addition, the carbon chain of the alkylene linker can be 
optionally interrupted With one or more groups including an 
alkene, alkyne, phenylene, ether, thioether, amine, (Cl-C6) 
alkylamino, di(Cl-C6)alkylamino, ester, thioester, amide or 
carbamate. In a speci?c example, the linker is an alkylene 
group that is interrupted With one or more amide groups. In a 
particular example, the alkylene group is interrupted With tWo 
amide groups. 
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[0043] In a particular embodiment, the linker is represented 
by the folloWing structural formula: 
Wherein each r, s, andt are independently and optionally 0, l, 
2, or 3, W is l, and X1, X2,Yl andY2 are independently CR2, 
O, S, or NR, Wherein R is an alkyl group, an acyl group, an 
aryl group, a cycloalkyl group, or a heterocycle group. Alter 
natively, R can form an aryl group, a cycloalkyl group or a 
heterocycle group With another carbon atom Within the linker. 
Z1 and Z2 is independently O, S or H2. 
[0044] In a speci?c embodiment, the linker is represented 
by the folloWing structural formula: 
0 0 
wherein r, s, andt are independently and optionally 0, l, 2, or 
3. 
The symbol 
indicates the point of connection to ?uorophore and the anti 
malarial. Either the ?uorophore or the antimalarial can be 
attached to either the left side or the right side of the linker. 
Any substitutable hydrogen on a carbon atom of this linker 
may be substituted by halo, OH, NO2, CN, COOH, COO(Cl - 
C6alkyl), amino, (C, C6)alkyl, (Cl-C6)alkoxy, (Cl-C6)alky 
lamino, or di(Cl-C6)alkylamino, Wherein the (Cl-C6)alkyl 
and (Cl-C6)alkoxy in any of the preceeding groups may be 
optionally substituted With halogen, (Cl-C6)alkoxy, COOH, 
COO(Cl-C6alkyl), OH, NO2 or CN. In a speci?c embodi 
ment, coumarin is substituted With dimethylamino. Any sub 
stitutable hydrogen on a nitrogen atom may be substituted by 
l to 3 groups selected from (Cl-C6)alkyl, optionally substi 
tuted With halogen, (Cl-C6)alkoxy, COOH, COO(C1 
C6alkyl), OH, NO2 or CN. In a speci?c embodiment, r andt 
are independently l or 2 and s is 2 or 3. In a particular 
embodiment, the linker is 
US 2012/0100555 A1 
[0045] In a particular embodiment, the linker is 
[0046] In a particular embodiment, the linker is 
O 
H ME/VOWO/VNW 
O 
[0047] In a speci?c embodiment, the coumarin-tagged anti 
malarial includes coumarin and linker, Which are represented 
by the following structural formula: 
O 
\i/%\ H lip/N N/ ’ 
or salts thereof. 
[0048] As used herein, “antimalarial” or “antimalarial 
compound” means a compound used to treat or prevent 
malaria in a patient. An antimalarial compound may be used 
therapeutically, may be in development for therapeutic use, 
may be knoWn to have antimalarial properties, but not used 
therapeutically, or may have an unknoWn effect in addition to 
killing the parasite. Non-therapeutic uses of antimalarials 
include malarial research. Examples of antimalarials include 
quinine, atovaquone, chloroquine, cycloguanil, hydroxy 
choloroquine, amodiaquine, pyrimethamine, sulphadoxine, 
pro guanil, me?oquine, halofantrine, pamaquine, primaquine, 
artemesinin, artemether, artesunate, artenimol, lumefantrine, 
dihydroartemisinin, piperaquine, arteether, doxycycline and 
clindamycin. 
[0049] Antimalarial derivatives are also included in the 
invention. Antimalarial derivatives are antimalarial com 
pounds that have been modi?ed as compared to the antima 
larial. For example, an antimalarial can be derivatiZed to 
incorporate a chemical moiety into the antimalarial such as a 
hydroxyl, halogen, a carboxylic acid, an ester, an alkoxy or a 
alkyl or any combination thereof. An antimalarial can be 
derivatiZed to remove a chemical moiety present in the anti 
malarial such as a hydroxyl, halogen, a carboxylic acid, an 
ester, an alkoxy or an alkyl or any combination thereof. An 
antimalarial can also be modi?ed by, for example, by short 
ening or lengthening alkyl groups Within the antimalarial to 
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form an antimalarial derivative. Chemical moieties can be 
added, removed or modi?ed independently of each other. 
Speci?cally, the antimalarial is chloroquine or a derivative 
thereof. Chloroquine is represented by Structural Formula I 
and a derivative of chloroquine is represented by Structural 
Formula II: 
and salts thereof. In Structural Formula II, n is 0, l, 2, 3, or 4; 
R1, R2 and R3 are independently selected from is H, (Cl-C6) 
alkyl, halo(Cl-C6)alkyl, (Cl-C6)alkoxy or (Cl-C6)cy 
cloalkyl; and R4 is H, halogen, haloalkyl, hydroxy, CN or 
N02. R2 and R3 may be used for attachment to the linker or 
?uorophore. In one embodiment of Structural Formula II, R1 
is H; R2 is ethyl, R3 attaches to a linker; and R4 is Cl. In a 
speci?c embodiment of Structural Formula II R1 is H; R2 is 
ethyl, R3 attaches to a linker; R4 is Cl; and n is 2. 
[0050] In addition to antimalarials, compounds Without 
established antimalarial properties are also contemplated. 
These compounds may be those relevant for understanding of 
nutritional requirements and signaling events Within the para 
site. 
[0051] In a speci?c embodiment, coumarin-tagged antima 
larial is coumarin-tagged chloroquine, or a salt thereof, 
Wherein the coumarin is optionally substituted. 
[0052] In a particular embodiment of the invention, the 
coumarin-tagged chloroquine is represented by the folloWing 
structural formula: 
or a salt thereof, Wherein n is independently and optionally 0, 
l, 2, or 3. 
[0053] In another particular embodiment of the invention, 
the coumarin-tagged chloroquine is represented by the fol 
loWing structural formula: 
US 2012/0100555 A1 
or a salt thereof. 
[0054] Fluorophore tags for use in the invention, such as 
coumarin, are biologically inert and therefore any cellular 
response should be attributable to antimalarial attached to the 
tag. As seen in FIG. 2, the coumarin-tagged chloroquine 
(CM-CQ) has activity comparable to chloroquine (CQ). The 
similarity of the activities CQ and CM-CQ alloWs for live 
imaging of cells to determine cellular localiZation (FIG. 1) of 
the drug as a means to understand drug action and resistance 
in Plasmodium species. 
[0055] Another embodiment of the invention is a method 
for identi?cation of a target in a cell, comprising the steps of 
exposing the cell to a ?uorophore-tagged antimalarial 
described herein, alloWing the ?uorophore-tagged antima 
larial bind to its target, and capturing the ?uorophore-tagged 
antimalarial bound to the target With an a?inity ligand (in 
immobiliZed or free form) speci?c for the ?uorophore tag; 
and identifying the target bound to the ?uorophore-tagged 
antimalarial. The af?nity ligand can be an antibody speci?c 
for the ?uorophore. 
[0056] As used herein, a “target” is the biological molecule 
to Which the antimalarial binds. A target includes metabolic 
by-products, enZymes, receptor and structural proteins, 
nucleic acids, signaling and membrane molecules. 
[0057] An immobiliZed a?inity ligand is used in a pull 
doWn assay Which also includes af?nity chromatography. 
A?inity chromatography is a chromatographic method of 
separating biochemical mixtures, based on a highly speci?c 
biologic interaction such as that betWeen antigen and anti 
body, enZyme and substrate, or receptor and ligand. Speci? 
cally, targets of the antimalarials can be identi?ed or con 
?rmed by the use of a ?uorophore-tagged antimalarial in a 
pull-doWn assay using antibodies directed against ?uorescent 
tags. The method comprises the steps of exposing the cell to 
the ?uorophore-tagged antimalarial, alloWing the ?uoro 
phore-tagged antimalarial to interact and bind to its target, 
capturing the ?uorophore-tagged antimalarial, noW bound to 
its target, on an immobiliZed a?inity ligand speci?c for the 
?uorophore tag; and identifying the target bound to the ?uo 
rophore-tagged antimalarial. 
[0058] In particular, immunoprecipitation (IP) protocols 
Would begin by treating live infected cells (incorporating a 
Plasmodium species) With the coumarin-tagged antimalarial. 
The cells are Washed With RIPA buffer (the medium used for 
IP protocols), lysed in the presence of protease inhibitors, and 
sub-cellular fractionated. This entire process Would be moni 
tored by ?uorescence spectroscopy to minimiZe the loss in the 
lAF-labeled probe during this process. The isolated sub-cel 
lular fractions are then subjected to a?inity chromatography 
using anti-IAF mAb agarose resin. Calibrations of this 
method can be conducted using both engineered and native 
systems, indicating that the method can be used to isolate 
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speci?c proteins at a concentration greater than 500 pg/ml 
from lysates containing a net protein content of 1 mg/ml. 
[0059] The IP method provides advantages as compared to 
the biotin-strepavidin methods as one can effectively com 
petitively-release the proteins readily from the resin by elu 
tion With 0.05 mM 7-dimethylaminocoumarin-4-acetic acid 
in phosphate buffer (PBS) or a gel loading buffer. This alloWs 
gels to return immunoprecipitated proteins Without back 
ground from native interactions (as commonly seen in biotin/ 
streptavidin procedures) or antibody contamination (arising 
by the conventional boiling of IP resins to release their protein 
content). Concentration of eluent to 20-50 [1.1 by means of spin 
concentration With 5,000 MWCO removes all small mol 
ecules. After checking the protein content by spectrophoto 
metrically With coumarin-labeled ?uorescence, samples With 
greater than 10 ng/mL or protein are pooled and subjected to 
SDS page gel analysis and Western blotting using the anti 
coumarin mAb for detection. 
[0060] The ?uorophore, such as coumarin, may be an 
immunoaf?nity-?uorescent (IAF) tag. Thus, in another 
embodiment of the invention, the coumarin-tagged antima 
larial compound is used in co-immunopreciptation (co-IP) 
studies to identify biomolecules. Methods of performing co 
immunoprecipitation experiments are knoWn in the art. Rep 
resentative examples of co-IP studies are described in Hughes 
C. C., et al., Angew. Chem. Int. Ed. EngL, 2009, 48, 728; 
Rodriguez A. D., et al., J. Am. Chem. Soc. 2008, 130, 7256; 
and Alexander M. D., et al., Chembiochem. 2006, 7, 409, the 
entire teachings of Which are incorporated herein by refer 
ence. 
[0061] As used herein “exposing the cell to the ?uoro 
phore-tagged antimalarial” means the cell and the ?uoro 
phore-tagged antimalarial are present in the same container or 
in the same solution and may come into contact. Exposing the 
cell the ?uorophore-tagged antimalarial includes adding the 
?uorophore-tagged antimalarial, either in solution or as a 
solid, to the culture media used to cultivate the cells. 
[0062] The ?uorophore-tagged antimalarial may be added 
at any time during the cultivation. For example, the ?uoro 
phore-tagged antimalarial can be added to the media before 
the cells are added, can be added at the time the cells are 
added, or can be added after the cells are added. The exposure 
period can be the entire time of the cultivation of the cells or 
can be a shorter period than the cultivation of the cells. For 
example, the ?uorophore-tagged antimalarial can be added to 
the media before or When the cells are added and left in the 
culture media until the cells are harvested. Alternatively, the 
?uorophore-tagged antimalarial can be added after the cells 
are added including after 5 minutes, 15 minutes, 30 minutes, 
45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 
7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 
hours, 20 hours, 24 hours, 32 hours, 40 hours, or 48 hours 
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after. Alternatively, the ?uorophore-tagged antimalarial can 
be added after the cells are synchronized (for example, the 
parasites are all at the ring stage). Synchronization techniques 
include, for example, sorbitol synchronization to select for 
ring-stage parasites. (See Lambros, C., and Vanderberg, J. P. 
(1979) J Parasitol 65, 418-420, the entire teachings of Which 
are incorporated herein by reference.) The exposure can be 
ended by removing the media from the cells and adding neW 
media that does not contain the ?uorophore-tagged antima 
larial. The exposure time can depend upon the length of time 
needed to achieve a biological result such as cell death. 
[0063] As used herein “capturing” is a chemical or physical 
process by Which the ?uorophore-tagged antimalarial bound 
to the target is separated from the cell or cell debris folloWing 
lysis of the cell. For example, the cells can be collected from 
the media through centrifugation. The cells can be lyzed by 
routine techniques, and thereby release the cell contents 
including the ?uorophore-tagged antimalarial bound to the 
target into a solution. 
[0064] The ?uorophore-tagged antimalarial bound to the 
target in the solution (or “mobile phase”) is separated from 
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other molecules in solution based on differences in chemical 
or physical interaction With a stationary material (solid 
phase). Af?nity chromatography (also called a?inity puri? 
cation) makes use of speci?c binding interactions betWeen 
the ?uorophore of the ?uorophore-tagged antimalarial and 
the stationary material. A particular ligand is chemically 
immobilized or “coupled” to a solid support so that When the 
solution containing a ?uorophore-tagged antimalarial is 
passed over the column, only those molecules having speci?c 
binding af?nity to the ligand (e.g., the ?uorophore-tagged 
antimalarial bound to the target) are puri?ed. Af?nity puri? 
cation generally involves the following steps: lncubate crude 
sample With the immobilized ligand support material to alloW 
the target molecule in the sample to bind to the immobilized 
ligand. Wash aWay nonbound sample components from solid 
support. Elute (dissociate and recover) the target molecule 
from the immobilized ligand by altering the buffer conditions 
so that the binding interaction no longer occurs. 
[0065] Another embodiment of the invention is a method 
for identi?cation of a target in a cell, comprising the steps of 
exposing the cell to the ?uorophore-tagged antimalarial of the 
folloWing structural formula: 
or a salt thereof, Wherein n is independently and optionally 0, 
l, 2, or 3; alloWing the ?uorophore-tagged antimalarial to 
bind to its target, capturing the ?uorophore-tagged antima 
larial bound to the target on an immobilized a?inity ligand 
speci?c for the ?uorophore tag; and identifying the target 
bound to the ?uorophore-tagged antimalarial. 
[0066] Another embodiment of the invention is a method 
for identi?cation of a target in a cell, comprising the steps of 
exposing the cell to the ?uorophore-tagged antimalarial of the 
folloWing structural formula: 
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or a salt thereof; allowing the ?uorophore-tagged antimalarial 
to bind to its target, capturing the ?uorophore-tagged antima 
larial bound to the target on an immobilized a?inity ligand 
speci?c for the ?uorophore tag; and identifying the target 
bound to the ?uorophore-tagged antimalarial. 
[0067] The target can be identi?ed by routine methods 
knoWn to those of skill in the art including mass spectrometry 
(for example, electrospray ioniZation (ESI) and matrix-as 
sisted laser desorption/ionization (MALDI)), de novo protein 
sequencing, and gel electrophoresis. In one embodiment of 
the invention, the target is identi?ed by N-terminal or internal 
protein sequencing, mass spectrometry, gel electrophoresis, 
or gene silencing With siRNA (See Natt F. siRNAs in drug 
discovery: target validation and beyond. Curr Opin Mol. 
Ther. 2007 June; 9(3):242-247, the entire teachings of Which 
are incorporated herein by reference) or RNAi. (See Kourtidis 
A, et al. RNAi applications in target validation. Ernst Scher 
irig Res Found Workshop. 2007; (61): 1-21, the entire teach 
ings of Which are incorporated herein by reference.) 
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[0068] For ESI, intact proteins are ioniZed and then intro 
duced to a mass analyser. For MALDI, proteins are enzymati 
cally digested into smaller peptides using a protease such as 
trypsin. Subsequently these peptides are introduced into the 
mass spectrometer and identi?ed by peptide mass ?ngerprint 
ing or tandem mass spectrometry (e. g. nano-LC/MS/MS 
analysis). Additional methods for target validation include 
gene silencing With siRNA or RNAi. 
[0069] Another embodiment of the invention is a method 
for determining the location of a ?uorophore-tagged antima 
larial Within or on a cell comprising the steps of exposing the 
cell to a ?uorophore-tagged antimalarial described herein; 
and assaying the cell to determine the location of the ?uoro 
phore-tagged antimalarial Within or on the cell. 
[0070] Another embodiment of the invention is a method 
for determining the location of a ?uorophore-tagged antima 
larial Within or on a cell comprising the steps of: exposing the 
cell to the ?uorophore-tagged antimalarial of the folloWing 
structural formula: 
NH N 
or a salt thereof, Wherein n is independently and optionally 0, 
1, 2, or 3 and assaying the cell to determine the location of the 
?uorophore-tagged antimalarial Within or on the cell. 
[0071] Another embodiment of the invention is a method 
for determining the location of a ?uorophore-tagged antima 
larial Within or on a cell comprising the steps of: exposing the 
cell to the ?uorophore-tagged antimalarial of the folloWing 
structural formula: 
NH N 
HN HN_/— , 
\ Hfi. O O 
— \_ 









